Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

Economia

COMUNICATO STAMPA - Responsabilità editoriale di Business Wire

HighRes Biosolutions and Novo Nordisk partner to transform drug discovery in automated Lab of the Future

Business Wire

HighRes Biosolutions and Novo Nordisk A/S today announced that they will collaborate to design a state-of-the-art robotic platform for high-throughput biologics engineering and characterisation. The integration of a multi-system robotics platform with sophisticated software control architecture will enable a digital transformation and accelerated discovery for Novo Nordisk’s peptide and large molecule therapeutics research.

“In order to maintain our leadership within biologics engineering we are investing in a fully automated and digital design platform. This investment is linked to our build-up in AI and advanced analytics and demonstrates Novo Nordisk’s commitment as a world leading biologics research company,” said Lars Fogh Iversen, senior vice president, Global Research Technologies, Novo Nordisk.

The platform will comprise several highly automated and integrated cells for production, characterisation and functional analysis of thousands of biologic compounds every month. Its scope covers the full range from small synthetic peptides to recombinantly expressed large proteins and will also include chemical modification of the molecules. The ambition is to build a system that is fully integrated with a modern data infrastructure and the data science and machine learning capabilities in Novo Nordisk.

Ira Hoffman, CEO of HighRes Biosolutions, said: “We are very excited to be working with Novo Nordisk on their Lab of the Future. We believe that the combination of our capabilities, products and vision make us the ideal partner for their digital transformation.”

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,200 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

About HighRes Biosolutions

HighRes Biosolutions improves human health through life science robotics. The company designs and builds innovative laboratory automation systems, dynamic scheduling software, and lab automation instruments that accelerate and streamline discovery. HighRes offers highly flexible, modular solutions that provide its clients with the ability to scale and reconfigure their automation equipment as their assays or technology changes. Visit www.highresbio.com or follow HighResBio on LinkedIn.

For further information please contact: sales@highresbio.com

Media Contact:
HighRes Biosolutions:
Brian O’Sullivan
VP Sales and Marketing
+1 781 932 1912 ext. 1201

Permalink: http://www.businesswire.com/news/home/20200124005116/en

Video Economia


Vai al sito: Who's Who

Modifica consenso Cookie